Vice President, Global Program Head, Neuroscience and Ophthalmics @ Novartis
Global Project Head, Neuroscience and Anesthesia @ Abbott
Senior Director @ Pfizer
A senior executive physician with more than 12 years of Pharmaceutical R&D experience in medium and large size companies. Extensive experience in leading groups and departments across all phases of drug development and a number of therapeutic areas. Global (US and International) drug development experience including orphan diseases involving direct leadership of multifunctional project teams, leadership of
A senior executive physician with more than 12 years of Pharmaceutical R&D experience in medium and large size companies. Extensive experience in leading groups and departments across all phases of drug development and a number of therapeutic areas. Global (US and International) drug development experience including orphan diseases involving direct leadership of multifunctional project teams, leadership of a portfolio of projects managed by several project leaders, and leadership of clinical development teams including direct hands on study physician experience. A creative and innovative thinker with a record of accomplishments in novel approaches to drug development.
Vice President, Global Clinical Development @ Oct '11 to Jan '14:
Head of the Early Clinical Group which comprises Clinical Pharmacology and Operations, Translational Medicine and the Early Clinical Medicine Physicians (35-40 people across 3 sites in US and Europe). Responsible for defining rational and efficient clinical development strategies and protocol design for all Early Development projects (Phase 1 and Phase 2 until entry into Phase 3) across all therapeutic areas in the Specialty Pharmaceutical Division. Chair the Early Development Committee which has oversight for all Specialty Pharma projects before they enter Phase 3 development (as of Jan 2012). Responsible for functional management of the Project General Managers of all Early Development Projects to ensure that projects meet strategic objectives and their development plans are designed to be patient-focused and differentiated leading to a favorable business case (as of Jan 2012). Directly Responsible for clinical development of the iron chelator SPD602 in orphan disease indications such as Thalassemia, Sickle Cell disease and Myelodysplastic syndromes.
As of February 2014, became Global Development Team Lead for Gaucher and Fabry in the Rare Diseases Therapeutic Area. Responsible for leading the multifunctional global development teams for products in development across these disease areas. From October 2011 to Present (4 years) Nyon, SwitzerlandVice President, Global Franchise Development Head, Established Medicines @ Lead the multidisciplinary Development group (approximately 50 colleagues) responsible for more than 180 compounds across all therapeutic areas in general medicine including Tropical Medicine (mainly malaria). These compounds were late in their life cycle management but were still generating more than $5 billion in sales annually. Co-lead with the Global Business Franchise Head the Global Franchise activities such as governance, global products life-cycle management, business development and licensing. From September 2010 to October 2011 (1 year 2 months) Basel Area, SwitzerlandVice President, Global Program Head, Neuroscience and Ophthalmics @ Provide leadership to three large Phase II, III and IIIb programs across psychiatry and neurology (Parkinson’s Disease, Fragile X syndrome, Huntington’s Disease, Major Depressive Disorder, Schizophrenia). Direct responsibility for the global development of the mGluR5 antagonist, AFQ056, in the orphan disease indication of Fragile X syndrome including agreement on registrational studies with the FDA and EMA. Serve as a core member of the Neuroscience and Ophthalmics Development Leadership Team responsible for the overall strategic and operational plans of the Development Franchise. From September 2008 to October 2011 (3 years 2 months) Basel Area, SwitzerlandGlobal Project Head, Neuroscience and Anesthesia @ Lead and direct the drug development programs for CNS compounds from Phase 1 through Phase 4, including Depakote and several compounds (> 9 NMEs) in Phase 1 and 2 development across several indications (ADHD, Schizophrenia, Alzheimer’s Disease, Epilepsy, Migraine, Bipolar disorder, Smoking Cessation)- Includes pre-IND planning for a biologic treatment for Alzheimer’s disease. Lead the sNDA for Depakote ER indication for acute mania and ultimately obtaining approval. Lead large Depakote Pediatric Program across epilepsy, migraine and bipolar disorder indications. Member of the Neuroscience Therapeutic Executive Committee responsible for defining the Neuroscience strategy for the company across Discovery, Development and Commercial. From March 2005 to August 2008 (3 years 6 months) Greater Chicago AreaSenior Director @ As an Associate Director, Early Clinical Leader in the first two years (Aug '01 to Aug '03), was responsible for the development of several compounds from Phase 1 until Proof of concept. Extensive experience in leading clinical teams and executing a large number of phase 1 clinical pharmacology studies, biomarker and imaging studies as well as proof of concept studies. Disease areas included anxiety, depression and schizophrenia.
In September 2003, was appointed as Senior Medical Director and Site Head for the New Haven Clinical Research Unit in New Haven, CT. Responsibilities included general management oversight of the facility, culture and vision of the site and achievement of staff and site goals; recruitment and oversight of the 50 staff necessary to run the Unit; manage day to day aspects of the clinical and laboratory operations in the unit and for cultivating relationships with the Yale University and the New Haven community; lead the Scientific Alliance between Yale University and Pfizer. From August 2001 to March 2005 (3 years 8 months) Groton, CT, USAAssistant Professor of Psychiatry @ Established the Schizophrenia Research Clinic at the Abraham Ribicoff Research Center. Conducted preclinical research on serotonergic modulation of the GABAergic system. Conducted a series of clinical research studies in healthy subjects and in patients with schizophrenia to better understand the biologic underpinnings of schizophrenia and psychosis in general. Conducted in vivo microdialysis studies in patients with temporal lobe epilepsy to characterize changes in the extracellular space during various states: hypoglycemia, stimulation, cognitive performance and sleep. From 1998 to 2001 (3 years) New Haven, CT, USA
M.D., Medicine @ Universite St. Joseph From 1987 to 1990 Walid Abi-Saab is skilled in: Clinical Development
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension